295 related articles for article (PubMed ID: 36685541)
1. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Qin Q; Zhu H
Front Immunol; 2022; 13():1044678. PubMed ID: 36685541
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.
Xiang G; Jiang T; Gan L; Wu Y; Zhang N; Xing H; Su H; Li Y; Peng D; Ni R; Liu Y
Front Immunol; 2023; 14():1223020. PubMed ID: 37720211
[TBL] [Abstract][Full Text] [Related]
4. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
Shao T; Zhao M; Liang L; Tang W
BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
6. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China.
Chen F; Long Y; Yang J; Zhong K; Liu B
BMJ Open; 2023 Dec; 13(12):e078924. PubMed ID: 38149425
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Lin YT; Zhou CC; Xu K; Zhang MD; Li X
Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
Meng M; Liu X; Liang X; Chen X; Li Y
Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China.
Long Y; Xu Y; Liao L; Zhou Y; Wang H
BMJ Open; 2023 Aug; 13(8):e072106. PubMed ID: 37586861
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer.
Zheng Z; Chen H; Cai H
Front Oncol; 2023; 13():1259574. PubMed ID: 38282674
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients.
Zheng H; Zeng Y; Wen F; Hu M
Front Immunol; 2024; 15():1382088. PubMed ID: 38711525
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Wang T; Li Y; Zheng X
BMC Health Serv Res; 2023 Jun; 23(1):691. PubMed ID: 37365540
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma.
Zheng H; Li J; Wen F; Su N
Front Oncol; 2023; 13():1216960. PubMed ID: 38023250
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q
Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
[TBL] [Abstract][Full Text] [Related]
18. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Ding D; Hu H; Li S; Zhu Y; Shi Y; Liao M; Liu J; Tian X; Liu A; Huang J
J Natl Compr Canc Netw; 2021 Aug; 19(10):1141-1147. PubMed ID: 34348237
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
Kang S; Liu H
Expert Rev Pharmacoecon Outcomes Res; 2023 Nov; ():1-8. PubMed ID: 37936507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
